Working with their colleagues at the University of Pennsylvania, researchers at the University of Kentucky have found that they can differentiate between sub-types of dementia inducing brain disease.
“For the first time we created criteria that could differentiate between frontotemporal dementia (FTD) and a common Alzheimer’s ‘mimic’ called LATE disease,” said Dr. Peter Nelson of the Sanders-Brown Center on Aging at the University of Kentucky. He says they validated the criteria rigorously. The study was recently published in BRAIN: A Journal of Neurology. The first author of the paper was John L. Robinson from the University of Pennsylvania and the corresponding author was Nelson.
A new blood test demonstrated remarkable promise in discriminating between persons with and without Alzheimer’s disease and in persons at known genetic risk may be able to detect the disease as early as 20 years before the onset of cognitive impairment, according to a large international study published in the Journal of the American Medical Association (JAMA) and simultaneously presented at the Alzheimer’s Association International Conference.
For many years, the diagnosis of Alzheimer’s has been based on the characterization of amyloid plaques and tau tangles in the brain, typically after a person dies. An inexpensive and widely available blood test for the presence of plaques and tangles would have a profound impact on Alzheimer’s research and care. According to the new study, measurements of phospho-tau217 (p-tau217), one of the tau proteins found in tangles, could provide a relatively sensitive and accurate indicator of both plaques and tangles — corresponding to the diagnosis of Alzheimer’s — in living people. Continue reading →
Cognitive decline is a major concern of the aging population. Already, Alzheimer’s disease affects approximately 5.4 million Americans and 30 million people globally. Without effective prevention and treatment, the prospects for the future are bleak. By 2050, it is estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system. Unlike several other chronic illnesses, Alzheimer’s disease is on the rise–recent estimates suggest that Alzheimer’s disease has become the third leading cause of death in the United States behind cardiovascular disease and cancer. Since its first description over 100 years ago, Alzheimer’s disease has been without effective treatment.
While researchers continue to seek out a cure, it is becoming clear that there are effective treatment options. More and more research supports the conclusion that Alzheimer’s disease is not a disease of only Beta Amyloid plaques and Tao tangles but a complex and systemic disease. In this study of patients with varying levels of cognitive decline, it is demonstrated how a precision and personalized approach results in either stabilization or improvement in memory.
Affirmativ Health sought to determine whether a comprehensive and personalized program, designed to mitigate risk factors of Alzheimer’s disease could improve cognitive and metabolic function in individuals experiencing cognitive decline. Findings provided evidence that this approach can improve risk factor scores and stabilize cognitive function.
Do you know that feeling you get in your gut? It turns out your gut may really be trying to tell you something. Our microbiome – the 100 trillion bacteria and organisms living in our gut – appears to have a profound influence on our health and risk of disease. And early scientific studies show there may be a link between the microbiome and the brain that could impact the risk of Alzheimer’s and other brain diseases.
The microbiome is a collection of bacteria, viruses and fungi that live mostly in our intestinal system. They play an important role in digestion and the production of certain vitamins, and they support our immune system. Researchers around the world study the gut microbiome, especially those bacteria unique to individuals, to learn more about their influence on our overall health.
Alzheimer’s disease is a progressive disorder in which the nerve cells (neurons) in a person’s brain and the connections among them degenerate slowly, causing severe memory loss, intellectual deficiencies, and deterioration in motor skills and communication. One of the main causes of Alzheimer’s is the accumulation of a protein called amyloid β (Aβ) in clusters around neurons in the brain, which hampers their activity and triggers their degeneration.
Studies in animal models have found that increasing the aggregation of Aβ in the hippocampus–the brain’s main learning and memory center–causes a decline in the signal transmission potential of the neurons therein. This degeneration affects a specific trait of the neurons, called “synaptic plasticity,” which is the ability of synapses (the site of signal exchange between neurons) to adapt to an increase or decrease in signaling activity over time. Synaptic plasticity is crucial to the development of learning and cognitive functions in the hippocampus. Thus, Aβ and its role in causing cognitive memory and deficits have been the focus of most research aimed at finding treatments for Alzheimer’s.
Older adults who have surgery with general anesthesia may experience a modest acceleration of cognitive decline, even years later. But there’s no evidence of a link to Alzheimer’s disease, according to new research from Mayo Clinic.
The research, published in the British Journal of Anaesthesia, examined brain scans from 585 patients, ages 70 to 91 ― 493 of whom had at least one surgery with general anesthesia. The analysis found cortical thinning in cerebral areas but no significant evidence of deposits of amyloid protein, a hallmark of Alzheimer’s disease. The cortex is the outermost layer of the brain’s nerve cell tissue, and thinning of that tissue is associated with diminished cognitive functions. Continue reading →
Herewith another entry in our arsenal against that destroyer of lives – Alzheimer’s Disease, from the Tufts Health & Nutrition Letter.
Alzheimer’s disease accounts for 60 to 80 percent of the loss of memory and other cognitive abilities collectively known as dementia. There is no known food or diet that can prevent or cure Alzheimer’s dementia, but diet may help delay onset and slow progression.
What sets Alzheimer’s apart from other forms of dementia is the excessive buildup of beta-amyloid protein fragments into plaques, as well as defective tau proteins that form tangles in the brain. These changes lead to the death of the nerve cells responsible for everything from memory to movement. There are currently no known dietary factors that can impact the formation of these plaques and tangles, but diet may act in other ways to influence Alzheimer’s and other forms of dementia.
Nearly half of Americans in their 50s and early 60s think they’re likely to develop dementia as they grow older, but only 5% of them have actually talked with a doctor about what they could do to reduce their risk, a new study finds.
Meanwhile, a third or more say they’re trying to stave off dementia by taking supplements or doing crossword puzzles – despite the lack of proof that such tactics work.
The new findings suggest a need for better counseling for middle-aged Americans about the steps they can take to keep their brains healthy as they age.
Meanwhile, pharmaceutical companies continue to work on potential dementia-preventing medications. But an over-estimation of future dementia risk by individuals may lead to costly over-use of such products, the researchers warn.
Donovan Maust, M.D., M.S., a geriatric psychiatrist specializing in dementia-related care and lead author of the JAMA Neurology letter, notes that even among the oldest Americans, the risk of dementia is lower than one in three people over age 85.
Risk starts rising around age 65, and is higher among people of Latino or African-American heritage. Continue reading →
As my family has had several cases of dementia, some in the form of Alzheimer’s, I am always captivated by tools for assessing risk as I am a senior citizen. This University of California San Diego School of Medicine study caught my eye.
Clinical trials to develop new therapeutic and preventive treatments for Alzheimer’s disease (AD) are costly, complicated and often preclude persons most at risk of developing the degenerative neurological condition: Older individuals with less mobility and significant medical issues, both making it more difficult for them to participate in traditional, clinic-based assessments with trained personnel.
In a new paper, published this month in the journal Alzheimer’s & Dementia, a multi-institution team led by researchers at Alzheimer’s Disease Cooperative Study (ADCS) at University of California San Diego School of Medicine published results of a novel four-year, randomized clinical trial evaluating different home-based methods to assess cognitive function and decline in participants over the age of 75.
Almost 600 persons participated in the home-based assessment (HBA) study; all had been previously diagnosed as either possessing normal cognitive abilities or suffering from Mild Cognitive Impairment, a condition that often precedes AD. Continue reading →
As I have written here numerous times, both sides of my family have a history of Alzheimer’s Disease, the most common form of dementia. As a guy in his late 70’s this is a critical subject for me. And I am not the only one. I live near Northwestern Memorial Hospital, a major Chicago health establishment. They have a Healthy Transitions program there for folks over 50 which provides programs explaining the changes we are experiencing and can expect to experience. The most popular are the ones dealing with cognitive impairment, Alzheimer’s and dementia. We are all concerned.
That’s why I hope there is a special place in hell for companies who prey on the fears of seniors about their mental health and capacities. I found this item from the U.S. Food and Drug Administration (FDA) most satisfying. Continue reading →
As a senior citizen whose family has Alzheimer’s and dementia on both sides I am keenly interested in anything on the subject. Herewith a study published in Nature Medicine.
Athletes know a vigorous workout can release a flood of endorphins: “feel-good” hormones that boost mood. Now there’s evidence that exercise produces another hormone that may improve memory and protect against Alzheimer’s disease, according to a study co-led by Ottavio Arancio, MD, PhD, a researcher at Columbia University’s Vagelos College of Physicians and Surgeons and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain.
Physical activity is known to improve memory, and studies suggest it may also reduce the risk of Alzheimer’s disease. But researchers don’t understand why.Continue reading →
Studying DNA from more than 1.5 million people, an international team of researchers — led by Washington University School of Medicine in St. Louis and the University of California, San Francisco — has identified points of DNA that increase the risk of cardiovascular disease and also heighten the risk for Alzheimer’s disease, according to an article in Neuroscience News.
Scientists have long been aware of connections between variations of the APOE gene, which is involved in cholesterol and lipid metabolism, and Alzheimer’s disease. That gene is known to double the risk for Alzheimer’s disease in some patients and increase risk by up to 12 times in others. But in the new study, the researchers identified other DNA points that also appear to be involved both in cardiovascular disease risk and the risk for Alzheimer’s. Continue reading →
Reduced levels of plasmalogens—a class of lipids created in the liver that are integral to cell membranes in the brain—are associated with an increased risk of Alzheimer’s Disease, according to new research presented this week at the Alzheimer’s Association International Conference (AAIC) 2018 by Mitchel A. Kling, MD, an associate professor of Psychiatry in the Perelman School of Medicine at the University of Pennsylvania and the Veterans Affairs Medical Center.
Plasmalogens are created in the liver and are dispersed through the blood stream in the form of lipoproteins, which also transport cholesterol and other lipids to and from cells and tissues throughout the body, including the brain. Kling, and the multi-institutional Alzheimer’s Disease Metabolomics Consortium led by Rima F. Kaddurah-Daouk, PhD, at Duke University School of Medicine, developed three indices for measuring the amount of these lipids related to cognition, in order to identify whether reduced levels in the bloodstream are associated with an increased risk of Alzheimer’s disease, mild cognitive impairment (MCI), overall cognitive function, and/or other biomarkers of neurodegeneration in Alzheimer’s disease. The three indices measured: the ratios of plasmalogens to each other; the ratios of plasmalogens to their closely-related, more conventional lipid counterparts; and a combination of these two quantities. Continue reading →
A new study reports high sugar and fat based diets that lead to obesity, coupled with the normal aging process, may increase the risk of Alzheimer’s disease. By my reckoning that means the older we get the more we need to pay attention to what we are eating and the amount we are exercising. Eat less; move more; live longer. For heaven’s sake, don’t wait till you are a senior to get on the exercise and good eating regime. Clearly, the earlier you start, the better of you are.
A new study suggests that when a high-fat, high-sugar diet that leads to obesity is paired with normal aging, it may contribute to the development of Alzheimer’s disease. In addition, researchers discovered that certain areas of the brain respond differently to risk factors associated with Alzheimer’s. The study is published in Physiological Reports.
Alzheimer’s disease, the most common form of dementia, is a progressive brain disorder that leads to loss of cognitive skills and memory and causes significant changes in behavior. Aging is a significant risk factor for Alzheimer’s. Previous studies suggest that diet-related obesity is also associated with development of the disease.Continue reading →
If you have been reading this blog for a while you are aware that I have a particular focus on the brain afflictions – dementia and its move common manifestation, Alzheimer’s. Three members on both sides of my family suffered from a form of dementia. While there is no cure or preventative for Alzheimer’s, it seems that exercise is our best chance of possessing a functioning brain in our old age. Hence, my focus on movement of every kind. Now, it seems that we may be getting a new arrow in our quiver to fight mental illness.
Researchers report tau pathology can be reversed in Alzheimer’s patients with the help of a drug. Their study reveals reversing tau pathology in mouse models of dementia resulted in a reversal of cognitive deficits in spatial learning.
Compared with untreated animals, tau mice that had received zileuton performed significantly better on the tests. Their superior performance suggested a successful reversal of memory deficiency. NeuroscienceNews.com image is in the public domain.
Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the way of significant clinical advance. But now, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) are breaking through that barrier. They show, for the first time in an animal model, that tau pathology – the second-most important lesion in the brain in patients with Alzheimer’s disease – can be reversed by a drug.
“We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,” explained senior investigator Domenico Praticò, MD, Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple at LKSOM. The study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia. Continue reading →
It’s good to see that exercise is being considered as one of the tools in dealing with cognitive decline in seniors. Eat less; move more; live longer. You don’t have to wait till you are in your senior years to practice them.
A comprehensive program providing older people at risk of dementia with healthy eating guidance, exercise, brain training, and management of metabolic and vascular risk factors appears to slow down cognitive decline, according to the first ever randomized controlled trial of its kind, published in The Lancet.
In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) study, researchers led by Professor Miia Kivipelto from the Karolinska Institutet in Stockholm, Sweden, National Institute for Health and Welfare in Helsinki, and University of Eastern Finland, assessed the effects on brain function of a comprehensive intervention aimed at addressing some of the most important risk factors for age-related dementia, such as high body-mass index and heart health. Continue reading →